Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Shanghai Zhongshan Hospital40 enrolled

Overview

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Gastroesophageal Varices JAK2 Mutation Myeloproliferative Neoplasm

Interventions

Anticoagulation AgentsDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patients aged 18-75 * diagnosed as portal hypertension by contrast-enhanced computed tomography * diagnosed as JAK2 positive Exclusion Criteria: * not had portal contrast-enhanced computed tomography * not had JAK2 mutation test * other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors

Outcomes

Primary Outcomes

Changes of portal vein thrombosis

The changes of portal vein thrombosis including progression, disappear or unchanged.

Time frame: 1 year

Secondary Outcomes

The occurrence of variceal bleeding

The occurrence of variceal bleeding including haematemesis and melena

Time frame: 1 year

Overall survival

Overall survival rate

Time frame: 1 year

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Overview

Conditions

Interventions

Eligibility

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts